ALIM vs. PRLD, ATAI, AEON, RNAC, OCUL, XOMA, FHTX, PBYI, SBTX, and AKBA
Should you be buying Alimera Sciences stock or one of its competitors? The main competitors of Alimera Sciences include Prelude Therapeutics (PRLD), Atai Life Sciences (ATAI), AEON Biopharma (AEON), Selecta Biosciences (RNAC), Ocular Therapeutix (OCUL), XOMA (XOMA), Foghorn Therapeutics (FHTX), Puma Biotechnology (PBYI), Silverback Therapeutics (SBTX), and Akebia Therapeutics (AKBA). These companies are all part of the "pharmaceutical preparations" industry.
Alimera Sciences (NASDAQ:ALIM) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability, institutional ownership, dividends and risk.
Prelude Therapeutics has a net margin of 0.00% compared to Alimera Sciences' net margin of -29.40%. Alimera Sciences' return on equity of 0.00% beat Prelude Therapeutics' return on equity.
Alimera Sciences received 328 more outperform votes than Prelude Therapeutics when rated by MarketBeat users. Likewise, 57.99% of users gave Alimera Sciences an outperform vote while only 48.98% of users gave Prelude Therapeutics an outperform vote.
Alimera Sciences has higher revenue and earnings than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Alimera Sciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Alimera Sciences had 1 more articles in the media than Prelude Therapeutics. MarketBeat recorded 2 mentions for Alimera Sciences and 1 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 1.87 beat Alimera Sciences' score of 0.94 indicating that Prelude Therapeutics is being referred to more favorably in the news media.
Alimera Sciences has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500. Comparatively, Prelude Therapeutics has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500.
Alimera Sciences currently has a consensus target price of $6.50, indicating a potential upside of 93.45%. Prelude Therapeutics has a consensus target price of $6.67, indicating a potential upside of 106.72%. Given Prelude Therapeutics' higher probable upside, analysts plainly believe Prelude Therapeutics is more favorable than Alimera Sciences.
70.3% of Prelude Therapeutics shares are owned by institutional investors. 31.4% of Alimera Sciences shares are owned by company insiders. Comparatively, 79.5% of Prelude Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Alimera Sciences beats Prelude Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Alimera Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALIM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Alimera Sciences Competitors List
Related Companies and Tools